MaxCyte, Inc. (MXCT) is a US-based global life sciences company committed to the discovery, development, and commercialization of next-generation cell and gene therapies. The company is a pioneer in cell transfection technology and continues to revolutionize its delivery with the latest technological and scientific advancements.
MaxCyte was established in 1998 with one mission - advancing and driving the pace of scientific discovery and biopharmaceutical drug development. Thus, evolving as a prominent player in the field of cell engineering. The company is traded on the London Stock Exchange under the symbol MXCT.
MaxCyte offers proprietary flow electroporation technology for the development and manufacturing of cell-based therapies. Its flagship product, ‘MaxCyte GT®’, is FDA-approved for use in clinical-stage CAR T programs. It also offers various other products and services that enable robust and scalable high-performance cell-engineering in reportedly less than 30 minutes.
In the past 21 years, MaxCyte has developed partnerships with leading cell therapy companies and has its technology leveraged in more than 100 partnered program licenses in cell therapy. With more than 70 licensed programs that are available for MaxCyte to commercialize, these partnerships provide the platform for MaxCyte to develop its own proprietary CARMA™ cellular therapies.
MaxCyte's unique CARMA platform is being used in ongoing US-based clinical trials in patients with relapsed or refractory acute myeloid leukemia and B-cell malignancies. CARMA is MaxCyte’s mRNA-based cellular therapy technology which enables the rapid production of CAR therapies from a patient’s own cells.
Notably, MaxCyte’s drug discovery and technology development isn't restricted to cancer treatments. The company is also involved in addressing other major diseases such as autoimmune and infectious diseases. This includes the fast-track development of innovative, next-generation vaccines and immunotherapies.
MaxCyte, Inc. is a company dedicated to creating transformative cell-based medicines with significant benefits to human health. It is constantly seeking groundbreaking technologies and approaches to produce universally compatible, scalable and affordable cell therapies quickly and efficiently.
With the pharmaceutical industry undergoing rapid development and breakthroughs in cell and gene therapies, MaxCyte’s platform plays an essential role in catalyzing this evolution. Its unique technology and innovative approach make it a crucial player in the realm of advanced biopharmaceuticals and cell therapy.